前列腺癌根治术后勃起功能障碍患者单次海绵体内注射自体脂肪来源再生细胞的12个月随访:开放标签I期临床试验
未发生严重不良事件,8例可控尿患者中53%在12个月时报告足以性交的勃起功能,国际勃起功能指数-5评分在6个月时显著升高并维持至12个月;尿失禁组及术前已有勃起功能障碍者未见改善。
要点
- 单次海绵体内注射自体脂肪来源再生细胞在12个月随访中未发生严重不良事件。
- 可控尿患者中53%在12个月时报告足以性交的勃起功能。
- 尿失禁患者及术前已有勃起功能障碍者未见勃起功能改善。
核心结论
- 在本项随访12个月的I期研究中,海绵体内注射脂肪来源再生细胞是安全的。
研究设计与样本
- 纳入时6例尿失禁、15例可控尿;主要终点为安全性,次要终点为性功能,在注射后1、3、6、12个月通过不良事件记录及国际勃起功能指数-5和勃起硬度评分问卷评估。
主要发现
- 未发生严重不良事件,但观察到8例与吸脂相关的可逆轻微事件。
- 可控尿组15例中8例(53%)在12个月时报告足以性交的勃起功能。
- 基线国际勃起功能指数-5评分中位数6.0(四分位距3)在治疗后1个月无变化,6个月时显著升高至7(四分位距17),12个月时维持(中位数8,四分位距14)。
- 尿失禁组及根治性前列腺切除术前已有勃起功能障碍者未见勃起功能改善。
临床怎么用
- 对于根治性前列腺切除术后勃起功能障碍且常规治疗无效的可控尿患者,可考虑单次海绵体内注射自体脂肪来源再生细胞作为安全但需进一步验证的干预。
- 治疗前应评估控尿状态及术前勃起功能,尿失禁或术前已有勃起功能障碍者可能获益有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore safety in adipose-derived regenerative cells (ADRC) therapy, treating erectile dysfunction (ED). METHODS: Twenty-one patients with ED after radical prostatectomy, with no signs of recovery using conventional therapy, received a single intracavernous injection of autologous ADRC and were followed for 1 year. Six men were incontinent, and 15 were continent at inclusion. The primary (safety of ADRC therapy) and secondary endpoints (sexual function) were evaluated at 1, 3, 6, and 12 months after ADRC injection by registration of adverse events and validated questionnaires using the international index of erectile function-5 and erection hardness score. RESULTS: No serious adverse events occurred, but 8 reversible minor events related to the liposuction were noted. Eight out of 15 (53%) patients in the continent group reported erectile function sufficient for intercourse at 12 months. Baseline median international index of erectile function-5 scores (6.0; interquartile range [IQR] 3) were unchanged 1 month after the treatment, but significantly increased after 6 to 7 (IQR 17). This effect was sustained at 12 months (median 8; IQR 14). We did not see any improvements in erectile function in the group of incontinent men or among men with ED prior to radical prostatectomy. CONCLUSION: Intracavernous injection of ADRC is safe in this phase 1 study with a 12-month follow-up.
引用
- Haahr MK, Harken Jensen C, Toyserkani NM, et al. A 12-Month Follow-up After a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-Label Phase I Clinical Trial. Urology. 2018. PMID: 29958973. doi:10.1016/j.urology.2018.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。